Table 3.

Univariable and multivariable analyses for clinically significant prostate cancer detection on transperineal vs transrectal MRI/TRUS fusion prostate biopsy.

Variables	Univariate			Multivariate
	OR	CI (95%)	p	OR	CI (95%)	p
Age, year	1.08	1.05–1.11	< 0.001	1.09	1.05–1.13	< 0.001
Family history PCa	0.82	0.54–1.23	0.3
Biopsy history
Previous negative biopsy vs naïve	0.37	0.23–0.59	0.003	0.61	0.33–1.11	0.056
Previous positive biopsy vs naïve	0.78	0.48–1.26	0.3	1.20	0.63–2.31	0.19
PSA, ng/ml	1.04	1.02–1.06	0.002	1.06	1.03–1.10	< 0.001
PSA density*, ng/ml2	1.00	1.00–1.01	0.2
Race
Black vs non-black	1.08	0.47–2.46	0.9
Asian vs NH-white	0.64	0.33–1.18	0.3
Hispanic vs HN-white	0.67	0.36–1.21	0.4
Black vs NH-white	0.98	0.42–2.26	0.6
Others vs NH-white	0.94	0.57–1.55	0.6
DRE, suspicious vs non-suspicious	18.9	10.7–35.8	< 0.001	4.72	2.69–8.54	< 0.001
Prostate volume, cc	0.98	0.97–0.98	< 0.001	0.97	0.97–0.98	< 0.001
No. MRI lesions	2.18	1.77–2.73	< 0.001	0.82	0.58–1.14	0.2
MRI lesion size, mm	1.06	1.03–1.10	< 0.001
PIRADS 3–5 vs PIRADS 1–2	29.0	14.2–70.1	< 0.001	37.9	13.8–121.1	< 0.001
No. TB cores taken	1.48	1.36–1.62	< 0.001
Prostate biopsy approach TP vs TR	0.93	0.64–1.35	0.7

PIRADS prostate imaging reporting and data system, MRI magnetic resonance imaging, OR odds ratio, CI confidence interval, PCa prostate cancer, CSPCa clinically significant PCa (Grade Group > 1), DRE digital rectal examination, DRE digital rectal examination, NH non-hispanic.

*PSA density was calculated per 0.01 unit.